Page 112 - Read Online

Page 16 of 18 Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94

https://kirby.unsw.edu.au/report/national-prison-entrants-bloodborne-virus-and-risk-behaviour-survey-report-2004-2007-2010-and.
[Last accessed on 28 Nov 2018]
135. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and
treatment. World J Hepatol 2015;7:2323-30.
136. Walmsley R. World prison population list. 11th ed. Birckbeck University of London: Institute for Criminal Policy Research; 2016.
137. United Nations. 45/111. Basic principles for the treatment of prisoners. Available from: http://www.un.org/documents/ga/res/45/
a45r111.htm. [Last accessed on 28 Nov 2018]
138. Bretschneider W, Elger BS. Expert perspectives on Western European prison health services: do ageing prisoners receive equivalent
care? J Bioeth Inq 2014;11:319-32.
139. de Viggiani N. Unhealthy prisons: exploring structural determinants of prison health. Sociol Health Illn 2007;29:115-35.
140. Teutsch S, Luciani F, Scheuer N, McCredie L, Hosseiny P, et al. Incidence of primary hepatitis C infection and risk factors for
transmission in an Australian prisoner cohort. BMC Public Health 2010;10:633.
141. Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, et al. Incidence and risk for acute hepatitis C infection during imprisonment in
Australia. Eur J Epidemiol 2010;25:143-8.
142. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM, et al. Evaluation of a prison outreach clinic for the diagnosis and
prevention of hepatitis C: implications for the national strategy. Gut 2003;52:1500-4.
143. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, et al. A framework for management of hepatitis C in prisons. Ann Intern
Med 2006;144:762-9.
144. Yap L, Carruthers S, Thompson S, Cheng W, Jones J, et al. A descriptive model of patient readiness, motivators, and hepatitis C
treatment uptake among Australian prisoners. PLoS One 2014;9:e87564.
145. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, et al. Safety and effectiveness of a nurse-led outreach program for assessment and
treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013;56:1078-84.
146. Fazel S, Baillargeon J. The health of prisoners. Lancet 2011;377:956-65.
147. Spaulding AC, Perez SD, Seals RM, Hallman MA, Kavasery R, et al. Diversity of release patterns for jail detainees: implications for
public health interventions. Am J Public Health 2011;101:S347-52.
148. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012;32:151-6.
149. Zickmund SL, Brown KE, Bielefeldt K. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease?
Dig Dis Sci 2007;52:2550-6.
150. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national
survey. J Viral Hepat 2001;8:377-83.
151. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, et al. Predictors of treatment in patients with chronic hepatitis C infection -
role of patient versus nonpatient factors. Hepatology 2007;46:1741-9.
152. Stoové MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol
Depend 2005;77:81-6.
153. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010;65:1327-9.
154. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30
countries: an economic analysis. PLoS Med 2016;13:e1002032.
155. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. Clin Infect Dis 2015;61:169-70.
156. US Senate Committee on Finance. The Price of Sovaldi and its impact on the U.S. Health Care System. Available from: https://www.
finance.senate.gov/imo/media/doc/2%20Introduction,%20Hepatitis%20C%20Background,%20Development%20of%20Sovaldi%20
and%20Gilead’s%20Acquistion%20of%20Pharmasset%20(Introduction,%20Sections%201&2).pdf. [Last accessed on 28 Nov 2018]
157. WHO. Global report on access to hepatitis C treatment. Focus on overcoming barriers. Available from: http://apps.who.int/iris/
handle/10665/250625. [Last accessed on 28 Nov 2018]
158. Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low and middle income
countries. BMC Infect Dis 2017;17:697.
159. WHO. Guidelines on hepatitis B and C testing. Available from: http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-
testing/en/. [Last accessed on 28 Nov 2018]
160. Stein K, Dalziel K, Walker A, Jenkins B, Round A, et al. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility
analysis. J Hepatol 2003;39:814-25.
161. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for
hepatitis C. Clin Infect Dis 2012;54:1259-71.
162. Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21.
163. Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-
dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol 2018; doi: 10.1111/jgh.14301.
164. Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and
approaches. BMC Infect Dis 2017;17:699.
165. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory
Dore and John Ward). J Viral Hepat 2014;21:1-4.
166. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, et al. Historical epidemiology of hepatitis C virus (HCV) in
selected countries. J Viral Hepat 2014;21:5-33.
167. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, et al. Strategies to manage hepatitis C virus infection disease burden-
Volume 4. J Viral Hepat 2017;24:44-63.
168. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, et al. Chronic hepatitis C virus infection in the United States, National